ASX ANNOUNCEMENT

25 August 2023

APPENDIX 4D AND HALF YEARLY FINANCIAL REPORT

Anteris Technologies Ltd (ASX: AVR) (Anteris or the Company) releases its Appendix 4D – Half Yearly (HY23) Financial Report and commentary for the period ended 30 June 2023.

HIGHLIGHTS

- A third cohort of patients were implanted with DurAVR™ Transcatheter Heart Valve (THV) in May 2023 taking the total of treated patients to twenty-one, including one compassionate case.
- DurAVR™ THV one year follow-up results were released for a total of thirteen patients, showing impressive and preserved valve performance with excellent safety.
- Patents were issued for the DurAVR™ THV single-piece tissue design.
- FDA granted expanded approval for the DurAVR™ THV Early Feasibility Study forming part of the process of finalizing the reimbursement level for the Study.
- FDA determined Anteris met regulatory requirements for manufacturing in Minnesota, USA.
- Anteris signed an agreement with v2vmedtech, Inc to develop a repair device for mitral and bicuspid regurgitation.
- Successful placement raising $35m cornerstoned by our two largest shareholders, Perceptive Advisors and L1 Capital.
- Anteris entered the All Ordinaries Index on 20 March 2023.

FINANCIAL SUMMARY

- Revenues of $2.3 million from ordinary activities for the half ending 30 June 2023 were generated from tissue product sales.
- Net loss after tax was $30.2m (2022: $22.1m). This increased loss was primarily due to significant R&D expansion including recruitment of additional personnel in preparation for the Early Feasibility Study in the United States.
- The closing cash position at 30 June 2023 was $20.3m with net working capital of $16.8m.

OUTLOOK

Since 30 June 2023, the Group commenced an Early Feasibility Study in the United States to treat patients with severe aortic stenosis using the DurAVR™ THV. Commencing the EFS represented a critical milestone for Anteris achieving Pre-Market Approval for US commercialisation of the DurAVR™ THV System.

Additionally, the Company successfully completed two implantations of DurAVR™ THV in valve-in-valve procedures as part of Health Canada's Special Access Program. This is an exciting outcome in a rapidly growing part of the market.

CEO COMMENT

"The last six months demonstrated outstanding results from our First-In-Human studies. The excellent results shown in the 30-day data for the first two patient cohorts were reinforced at the one-year marker and we saw consistently good results with the third cohort of patients at their 30-day assessments. These results clearly differentiate Anteris from market peers," CEO Wayne Paterson said.

ENDS

About Anteris Technologies Ltd (ASX: AVR)

Anteris Technologies Ltd (ASX: AVR) is a structural heart company committed to designing, developing, and commercialising innovative medical devices. Founded in Australia, with a significant presence in Minneapolis, USA, a MedTech hub, Anteris is science-driven, with an experienced team of multidisciplinary professionals delivering transformative solutions to structural heart disease patients.

The Company's lead product, DurAVR™, is a transcatheter heart valve (THV) for the treatment of aortic stenosis. DurAVR™ THV has been designed in partnership with the world's leading interventional cardiologists and cardiac surgeons and is the first transcatheter aortic valve replacement (TAVR) to use a single piece of bioengineered tissue. This biomimetic valve is uniquely shaped to mimic the performance of a healthy human aortic valve.

DurAVR™ THV is made using ADAPT® tissue, Anteris' patented anti-calcification tissue technology. ADAPT® tissue has been used clinically for over 10 years and distributed for use in over 50,000 patients worldwide.

The ComASUR™ Delivery System is designed to provide controlled deployment and accurate placement of the DurAVR™ THV with balloon-expandable delivery, allowing precise alignment with the heart's native commissures to achieve desired valve positioning.

Anteris Technologies is set to revolutionise the structural heart market by delivering clinically superior solutions that meet significant unmet clinical needs.

Authorisation and Additional Information

This announcement was authorised by the Board of Directors.

For more information:

Investor Relations (US)
Malini Chatterjee, Ph.D.
Managing Director
Blueprint Life Science Group
+1 917 330 4269

Investor Relations
Dejan Toracki
Corporate Development Director
Anteris Technologies
investors@anteristech.com
+61 409 340 641

Website	www.anteristech.com
Twitter	@AnterisTech
Facebook	www.facebook.com/AnterisTech
LinkedIn	https://www.linkedin.com/company/anteristech